Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer

Table 1 General situation of the patients, n (%)

Influencing factors	D-TACE (15 cases)	C-TACE (58 cases)	t/χ2 value	P value
Age (yr)	57.3 ± 11.5	59.9 ± 10.7	-0.8361	0.406
The longest tumor size before surgery (mm)	102.7 ± 44.4	75.0 ± 34.1	2.6261	0.011
Gender			1.907	0.167
Female	1 (6.7)	13 (22.4)
Male	14 (93.3)	45 (77.6)
Whether infected with HBV			11.317	0.0008
No	9 (60.0)	10 (17.2)
Yes	6 (40.0)	48 (82.8)
Whether there is liver cirrhosis			3.137	0.069
No	9 (60.0)	18 (31.0)
Yes	6 (40.0)	40 (69.0)
Is there a portal vein tumor thrombus			0.602	0.438
No	13 (86.7)	45 (77.6)
Yes	2 (13.3)	13 (22.4)
ECOG stamina score			3.769	0.152
0 points	2 (13.3)	13 (22.4)
1points	9 (60.0)	40 (69.0)
2points	4 (26.7)	5 (8.6)
Child-Pugh classification			1.668	0.196
A	6 (40.0)	34 (58.6)
B	9 (60.0)	24 (41.4)
Number of tumors			1.237	0.744
1	3 (20.0)	7 (12.1)
2	1 (6.7)	2 (3.4)
3	0 (0.0)	1 (1.7)
Multiple (> 3)	11 (73.3)	48 (82.8)
Barcelona staging			0.434	0.510
B	9 (60)	40 (69)
C	6 (40)	18 (31)

¹Result of t test.

ECOG: The Eastern Cooperative Oncology Group; D-TACE: Drug-loaded microspheres transcatheter arterial chemoembolization; C-TACE: Traditional/conventional transcatheter arterial chemoembolization.

Table 2 Laboratory indicators of patients before and after operation [median (P25, P75)]

Laboratory indicators	D-TACE (15 cases)	C-TACE (58 cases)	χ2 value	P value
AST changes before and after surgery (U/L)	44.1 (10.4, 153.0)	102.7 (52.4, 254.8)	-2.086	0.05
ALT changes before and after surgery (U/L)	133.1 (31.6, 181.8)	110.3 (46.5, 309.7)	-1.382	0.176
TBil changes before and after surgery (μmol/L)	7.9 (5.4, 14.9)	11.6 (5.8, 21.6)	-1.842	0.081
ALB changes before and after surgery (g/L)	4.9 (3.2, 5.4)	2.6 (0.3, 5.3)	1.992	0.055
WBC changes before and after surgery (× 109/L)	2.0 (0.9, 3.9)	2.1 (1.0, 4.4)	-0.214	0.832
RBC changes before and after surgery (× 1012/L)	0.3 (0.1, 0.5)	0.0 (-0.2, 0.3)	1.995	0.058
PLT changes before and after surgery (× 109/L)	30.0 (9.0, 43.5)	36.0 (16.5, 59.2)	-1.616	0.120
AFP changes 1 mo before and after surgery (ng/mL)	0.8 (-0.3, 31.9)	19.0 (0.0, 554.6)	-1.219	0.228

D-TACE: Drug-loaded microspheres transcatheter arterial chemoembolization; C-TACE: Traditional/conventional transcatheter arterial chemoembolization; AST: Aspartate aminotransferase; ALT: Alanine transaminase; TBil: Total bilirubin; ALB: Albumin; WBC: White blood cell; RBC: Red blood cell; PLT: Platelet; AFP: Alpha fetoprotein.

Table 3 Postoperative response of patients, n (%)

Postoperative response	D-TACE (15 cases)	C-TACE (58 cases)	t/χ2 value	P value
Body temperature (℃)	38.0 ± 0.9	38.3 ± 0.7	-1.4141	0.162
24 h PONV score postoperative			14.33	0.014
1	6 (40.0)	3 (5.2)
2	4 (26.7)	20 (34.5)
3	3 (20.0)	20 (34.5)
4	2 (13.3)	9 (15.5)
5	0 (0.0)	4 (6.9)
6	0 (0.0)	2 (3.4)
Postoperative pain score			32.967	0.000
0	5 (33.3)	15 (25.9)
2	7 (46.7)	0 (0.0)
4	3 (20.0)	39 (67.2)
6	0 (0.0)	4 (6.9)

¹Result of t test.

D-TACE: Drug-loaded microspheres transcatheter arterial chemoembolization; C-TACE: Traditional/conventional transcatheter arterial chemoembolization; PONV: Postoperative nausea and vomiting.

Table 4 Follow-up status of patients 1 and 3 mo after operation, n (%)

Follow-up status	D-TACE (15 cases)	C-TACE (58 cases)	χ2 value	P value
Efficacy evaluation one month postoperative			3.307	0.347
CR	2 (13.3)	20 (34.5)
PR	8 (53.3)	21 (36.2)
SD	3 (20.0)	7 (12.1)
PD	2 (13.3)	10 (17.2)
Evaluation of curative effect in 3 mo postoperative			4.091	0.252
CR	2 (13.3)	18 (31.0)
PR	7 (46.7)	21 (36.2)
SD	0 (0.0)	5 (8.6)
PD	6 (40.0)	14 (24.1)
Number of interventional treatments			10.444	0.005
1	15 (100.0)	32 (55.2)
2	0 (0.0)	24 (41.4)
3	0 (0.0)	2 (3.4)

D-TACE: Drug-loaded microspheres transcatheter arterial chemoembolization; C-TACE: Traditional/conventional transcatheter arterial chemoembolization; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Disease progression.